

Subject Index

A

- Anticonvulsant drugs
 - changes in plasma levels
 - altered patient response 8: 394
 - changed dosage 8: 394
 - clinical significance 8: 392-394
 - non-significant changes 8: 392-393
 - congenital malformations 8: 358-360, 366-385
 - effect on folate metabolism 8: 380-381
 - folate acid deficiency 8: 372-376
 - pharmacokinetics 8: 387-390
 - biologically active metabolites 8: 388-389
 - drug concentrations in body fluids 8: 390
 - plasma drug concentrations 8: 387-388
 - plasma levels 8: 390-394
 - sub-therapeutic 8: 392
 - therapeutic range 8: 390-391
 - toxic 8: 391-392
- Anticonvulsant therapy
 - laboratory control 8: 386-397
 - adjustment of dosage 8: 396
 - clinical application 8: 395
 - initial dosage 8: 395-396
 - maintenance dosage 8: 396-397
 - practical implementation 8: 395-397

C

- Carbenoxolone
 - compared with deglycyrrhizinised liquorice 8: 331-333
- Congenital malformations
 - aetiology in epilepsy 8: 358
 - anticonvulsants 8: 358-360
 - genetic factors 8: 361-362
 - severity of epilepsy 8: 360-361
 - socio-economic factors 8: 361
 - anticonvulsants 8: 366-385
 - phenytoin 8: 340-353

D

- Deglycyrrhizinised liquorice
 - dosage 8: 339
 - pharmacology 8: 336-338
 - antispasmodic activity 8: 337
 - metabolic effects 8: 338
 - mode of action 8: 337
 - prevention of ulcer formation 8: 337-338
 - side effects 8: 338-339
 - therapeutic trials 8: 331-336
 - combined with antacids 8: 336
 - duodenal ulcer 8: 333-336
 - gastric ulcer 8: 331-333
- Diphenylhydantoin
 - See phenytoin
- Drug Information 8: 321-329
 - international uniformity 8: 327-329
 - national differences 8: 321-322
 - uniformity of content 8: 322-326
- Drug reactions, adverse
 - deglycyrrhizinised liquorice 8: 338-339
- Duodenal ulcer
 - deglycyrrhizinised liquorice 8: 333-336
- Dysmorphogenesis
 - phenytoin 8: 340-353

E

- Epilepsy
 - dysmorphogenic potential of phenytoin 8: 340-353
 - folate acid deficiency 8: 366-385
 - incidence in pregnancy 8: 355-356
 - laboratory control of therapy 8: 386-397

F

- Folate metabolism 8: 367-372
 - absorption 8: 371

Subject Index

A

- Anticonvulsant drugs
 - changes in plasma levels
 - altered patient response 8: 394
 - changed dosage 8: 394
 - clinical significance 8: 392-394
 - non-significant changes 8: 392-393
 - congenital malformations 8: 358-360, 366-385
 - effect on folate metabolism 8: 380-381
 - folate acid deficiency 8: 372-376
 - pharmacokinetics 8: 387-390
 - biologically active metabolites 8: 388-389
 - drug concentrations in body fluids 8: 390
 - plasma drug concentrations 8: 387-388
 - plasma levels 8: 390-394
 - sub-therapeutic 8: 392
 - therapeutic range 8: 390-391
 - toxic 8: 391-392
- Anticonvulsant therapy
 - laboratory control 8: 386-397
 - adjustment of dosage 8: 396
 - clinical application 8: 395
 - initial dosage 8: 395-396
 - maintenance dosage 8: 396-397
 - practical implementation 8: 395-397

C

- Carbenoxolone
 - compared with deglycyrrhizinised liquorice 8: 331-333
- Congenital malformations
 - aetiology in epilepsy 8: 358
 - anticonvulsants 8: 358-360
 - genetic factors 8: 361-362
 - severity of epilepsy 8: 360-361
 - socio-economic factors 8: 361
 - anticonvulsants 8: 366-385
 - phenytoin 8: 340-353

D

- Deglycyrrhizinised liquorice
 - dosage 8: 339
 - pharmacology 8: 336-338
 - antispasmodic activity 8: 337
 - metabolic effects 8: 338
 - mode of action 8: 337
 - prevention of ulcer formation 8: 337-338
 - side effects 8: 338-339
 - therapeutic trials 8: 331-336
 - combined with antacids 8: 336
 - duodenal ulcer 8: 333-336
 - gastric ulcer 8: 331-333
- Diphenylhydantoin
 - See phenytoin
- Drug Information 8: 321-329
 - international uniformity 8: 327-329
 - national differences 8: 321-322
 - uniformity of content 8: 322-326
- Drug reactions, adverse
 - deglycyrrhizinised liquorice 8: 338-339
- Duodenal ulcer
 - deglycyrrhizinised liquorice 8: 333-336
- Dysmorphogenesis
 - phenytoin 8: 340-353

E


- Epilepsy
 - dysmorphogenic potential of phenytoin 8: 340-353
 - folate acid deficiency 8: 366-385
 - incidence in pregnancy 8: 355-356
 - laboratory control of therapy 8: 386-397

F

- Folate metabolism 8: 367-372
 - absorption 8: 371

- development of folate deficiency 8: 371-372
- effect of phenytoin 8: 363
- folate forms 8: 367-368
- in body fluids 8: 370-371
- in the central nervous system 8: 379-381
 - blood folic acid 8: 379-380
 - cerebrospinal fluid 8: 380
 - effect of anticonvulsants 8: 380-381
 - metabolic importance 8: 369-370
- Folic Acid Deficiency
 - dysmorphic potential of phenytoin 8: 352-353
 - in epilepsy 8: 375-376
 - neurological complications 8: 374-378
 - practical implications 8: 382
 - psychiatric implications 8: 376-378
 - related to anticonvulsants 8: 373-374
 - role of folic acid 8: 372-373
- G
- Gastric ulcer
 - deglycyrrhizinised liquorice 8: 331-333
- L
- Laboratory control
 - anticonvulsant therapy 8: 386-397
- Liquorice
 - See deglycyrrhizinised liquorice
- Liquorice, deglycyrrhizinised
 - See deglycyrrhizinised liquorice
- P
- Peptic ulcer
 - deglycyrrhizinised liquorice 8: 331-336
- Phenytoin
 - laboratory control of dosage 8: 386-397
- Phenytoin: dysmorphic potential 8: 340-353
 - animal investigations 8: 341-345, 362
 - in monkeys 8: 345
 - in rodents 8: 341-345
 - clinical investigations 8: 345-350
 - folic acid metabolism 8: 363
 - mechanism of effect 8: 350-353, 362-364
 - practical implications 8: 364-365
 - related to folic acid deficiency 8: 352-353
- Plasma levels
 - anticonvulsants 8: 390-394
- Pregnancy
 - dysmorphic potential of phenytoin 8: 340-353
 - outcome in epileptic women 8: 356-358
- T
- Therapeutic levels
 - Anticonvulsants 8: 390-391
- Toxic levels
 - anticonvulsants 8: 391-392





Pharmacology and the Future of Man

Proceedings of the 5th International Congress on Pharmacology, San Francisco, July 1972

Main Editor: *G.H. Acheson* (Cincinnati, Ohio)

Vol. 1	Drug Abuse and Contraception Volume Editor: <i>J. Cochin</i> (Boston, Mass.) SFr. 72.- / US \$ 26.25 / DM 69.- / £ 10.50 ISBN 3-8055-1470-0
Vol. 2	Toxicological Problems Volume Editor: <i>T.A. Loomis</i> (Seattle, Wash.) SFr. 59.- / US \$ 21.50 / DM 57.- / £ 8.60 ISBN 3-8055-1471-9
Vol. 3	Problems of Therapy Volume Editors: <i>G.T. Okita</i> (Chicago, Ill.) and <i>G.H. Acheson</i> (Cincinnati, Ohio) SFr. 116.- / US \$ 42.25 / DM 111.- / £ 16.90 ISBN 3-8055-1472-7
Vol. 4	Brain, Nerves, and Synapses Volume Editors: <i>F.E. Bloom</i> (Washington, D.C.) and <i>G.H. Acheson</i> (Cincinnati, Ohio) SFr. 109.- / US \$ 40.00 / DM 104.- / £ 15.90 ISBN 3-8055-1473-5
Vol. 5	Cellular Mechanisms Volume Editors: <i>R.A. Maxwell</i> (Research Triangle Park, N.C.) and <i>G.H. Acheson</i> (Cincinnati, Ohio) SFr. 104.- / US \$ 38.00 / DM 99.- / £ 15.10 ISBN 3-8055-1474-3
Vols. 1-5	(complete set) XC + 1984 p., 492 fig., 250 tab., 1973 SFr. 357.- / US \$ 130.00 / DM 339.- / £ 51.90 ISBN 3-8055-1387-9

The 5th International Congress on Pharmacology, held in San Francisco in July 1972, brought together the leaders of pharmacology from around the world. The highlight of the meeting was a series of lectures, debates, and symposia on topics of great interest to pharmacologists. They are published in five volumes, each representing the contributions in a major subdivision of pharmacology. Volume 1 deals with the social issues of drug abuse and contraceptive drugs. Volume 2 treats the problem of toxicology and environment. In Volume 3 the aspects of therapy with drugs in man are presented and in Volume 4 the topic drugs and the nervous system. Volume 5 deals with mechanism of drug action and regulation of cellular functions.



S. Karger
Basel · München · Paris · London · New York · Sydney

General Information

Publication data: Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. - / US \$49.00 / DM128. - / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaforth, N.S.W. Australia.

Subject index: Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

Editorial matter is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

Drug nomenclature: Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN - United States Pharmacopoeial Convention Inc) or the International Non-Proprietary Name (INN - WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

Correspondence: Letters to the editor are welcomed. They should be submitted in duplicate type-written on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

Manuscripts: Information on the preparation of manuscripts will be provided to authors.

Copyright: © 1974 ADIS Press. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

Subscription

Subscription orders can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4011 Basel (Switzerland), or else with the following:

Subscription Order Form

Please enter my subscription for *Drugs* beginning with

- | | | |
|---------------------------------------|---------------------------------------|---------------------------------------|
| <input type="checkbox"/> Vol. 1, 1971 | <input type="checkbox"/> Vol. 4, 1972 | <input type="checkbox"/> Vol. 7, 1974 |
| <input type="checkbox"/> Vol. 2, 1971 | <input type="checkbox"/> Vol. 5, 1973 | <input type="checkbox"/> Vol. 8, 1974 |
| <input type="checkbox"/> Vol. 3, 1972 | <input type="checkbox"/> Vol. 6, 1973 | |

Name _____

Title _____

Address _____

City _____

State/Zip _____

Bundesrepublik Deutschland:

S. Karger GmbH, Postfach 2,
D-8034 Germering/München

France: S. Karger S.A., 42bis, Bd de
La Tour-Maubourg, F-75 Paris 7e

Great Britain: John Wiley and Sons
Ltd., Baffins Lane, Chichester, Sussex

USA: Albert J. Phiebig Inc.,
US Representative of S. Karger, P.O.

Box 352, White Plains, NY 10602

Australia: Australasian Drug
Information Services Pty.Ltd., Agents
in Australasia for S. Karger, P.O. Box

194, Balgowlah/Sydney, NSW 2093

New Zealand: Australasian Drug

Information Services Pty.Ltd.,

New Zealand Office, P.O. Box 34-030,

Birkenhead, Auckland 10

